Investing in Biotech – How to Profit from the Biopharmaceutical Revolution
Product Description
Until the 1990s it barely existed, but biotech is now a multi-billion dollar industry producing windfall profits. Everyone is talking about human cloning, the genome project, and cures for cancer and AIDS, but what’s believable? Investing in Biotech is for anyone interested in profiting from the drug-development sector of this new, knowledge-based economy. Suitable for either an individual with $1,000 to invest or a financial manager responsible for million-dollar accounts, Investing in Biotech helps the reader understand one of the most discussed, but least understood sectors of the new economy. It gets beyond the genetics jargon and teaches how to rate a company’s chances in developing new medications or treatments for diseases and illnesses. If there’s truth in the old adage “Invest in what you know,” then Investing in Biotech will tell the potential investor everything necessary to make a profit in the new economy’s healthiest sector…. More >> Read more…
Categories: Biotech
Tags: Biotech, DescriptionUntil, development sector, dollar, dollar accounts, dollar industry, Economy, everyone, genome project, human cloning, Industry, jargon, knowledge based economy, new economy, old adage, product, profit, sector, windfall, windfall profits
Tech Investment Trends: Private Equity Bullish on Biotech, Clean Tech and Social Media
Venture funding has slowed considerably over the past year, but there are still opportunities for emerging technology companies to secure funding. While VCs are unquestionably more selective and doing far fewer deals, they will soon be ready to get off the sidelines to support companies in promising sectors.
So what sectors are stingy venture investors putting their money in? Biotech, which encompasses pharmaceuticals, diagnostics, medical devises, and clean tech were hot sectors that slumped in the first quarter of 2009, yet many still view it as a bastion of investment opportunity.
Categories: Biotech
Tags: Biotech, capital, David Prend, emerging technology companies, facebook, Funding, innovation fund, investment, mouli cohen, national venture capital association, promising sectors, sector, Tech, VCs, Venture, venture capital association, venture capital firm, venture capital sectors, venture investors, view
Biotech Mutual Funds
Mutual funds come in many packages, all tailored to suit the need of different investors. Biotech mutual funds are a category of these investments, whose major aim is to boost the performance of future technology. They also offer dividends to the investors and other benefits as well. For an investor who may want to invest in these stocks but does not know how to go about it, a little bit of research will go a long way in helping him decide the best way forward.
Categories: Biotech
Tags: Biotech, biotech drugs, biotech investment, biotech investments, Demand, drug, future technology, last several years, margin, Market, Mutual, MY RSS, Performance, Peter Gitundu, private venture capital, profit, profit margin, Read More, recession proof, risk factor, time, value increases, way
Biotech API Offers Growth Opportunities In The European API Market
‘Europe Active Pharmaceuticals Ingredients Market Analysis and Forecasts to 2020’ provides in-depth analysis of the European Active Pharmaceutical Ingredients (API) market and presents revenue forecasts up to 2020 for the key countries – UK, Germany, France and Italy. The report is based around the two major product types, namely, synthetic API and biotech API. Revenue forecasts are provided for both the product types. The synthetic API market is further analyzed based on the customer base – generic and innovative sectors. This study also provides detailed insights into the factors affecting the dynamics of the market with strategic analysis of the major trends. Market share analysis of the major companies in the whole European market is also covered in the report. ( http://www.bharatbook.com/Market-Research-Reports/Europe-Active-Pharmaceutical-Ingredients-Market-Analysis-and-Forecasts-to-2020.html )
Categories: Biotech
Tags: active pharmaceutical ingredients, API, Biotech, CAGR, containment policies, Europe, European, european api, France, generic sector, Germany, Growth, Italy, Market, market share analysis, Offers, Opportunities, sector, UK, Western Europe, Western European
What Is A Vector And A Host In Biotech?
I need to define: vector, host, and plasmid-why is a plasmid so useful in recombinant DNA?
Read more…
On the Brink of Generic Biotech Drugs, What’s the Cost to Innovation?
In a recently published report, the Federal Trade Commission suggested that the current allotment of a 12- to 14-year regulatory exclusivity period for product innovation to develop products at biotech companies is“too long to promote innovation.”
The same report, published June 4, also indicated that developing generic biotech drugs would help bring down the cost of U.S. health care. These less expensive versions are expected have prices discounts that are “between 10 and 30 percent of the pioneer products’ price,” the FTC said in its report, available here.
Categories: Biotech
Tags: american medical association, amp, Arlene Weintraub, Biotech, biotech drugs, Brink, Cohen, cost, drugs, Generic, house energy and commerce subcommittee, Industry, Innovation, Jeff Joseph, Joseph, mouli cohen, pioneer products, Report, U.S., U.S. Cannibalizing, United States, What's
